Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Principal Investigator: Emily Greengard

Protocol Number Title
2007NT091
COG AREN03B2: Renal Tumors Classification, Biology and Banking Study.
2008NTCG101
COG ANBL00B1 - Neuroblastoma Biology Studies
2012LS107
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Refractory Neuroblastoma and Pheochromocytoma
2013CG078
COG ADVL1217: A PHASE 1 STUDY OF AZD1775 (MK-1775, IND# 116495) CONCURRENT WITH LOCAL RADIATION THERAPY FOR THE TREATMENT OF NEWLY DIAGNOSED CHILDREN WITH DIFFUSE INTRINSIC PONTINE GLIOMAS
2014CG036
COG ADVL1411 - A Phase 1/ 2 Study of BMN 673 (IND# 121510), an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies
2014CG050
COG ADVL1322 (Novartis VEG116731) ? A Phase II Study of Pazopanib GW786034, NSC#737754 in Children, Adolescents and Young Adults with Refractory Solid Tumors
2014CG064
COG ARST1321 - Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
2014CG067
ANBL1232 - Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High- Risk Neuroblastoma
2014CG129
COG AEWS1221 - Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
2015CG012
COG ADVL1412 - A Phase 1/2 Study of Nivolumab (IND# 124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab Additional Title: ADVL1412-Bristol-Myers Squibb Company
2015CG151
ADVL1414 - A PHASE 1 STUDY OF SELINEXOR (KPT-330, IND #125052), A SELECTIVE XPO1 INHIBITOR, IN RECURRENT AND REFRACTORY PEDIATRIC SOLID TUMORS, INCLUDING CNS TUMORS
2015CG155
COG ADVL1522 - A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953, NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma
2015CG195
COG AOST1421- A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
2016CG116
MK3475-051/ADVL1621 - A Phase I/II Study of Pembrolizumab (MK3475) in Children with Advanced Melanoma or a PDL1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE051) Additional Title: ?ADVL1621 ? Merck Sharp and Dohme Corp.?
2016CG156
COG ADVL1513 - A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
2017CG036
COG ADVL1515 - A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors ADVL1515 - Eli Lilly and Company
2017CG074
ADVL1622 - Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
2017CG088
ADVL1514 - A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan

18 trials displayed